drugset / Trial / NCT05184049

Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patients

NCT05184049

Phase 4 Unknown 72 enrolled Xiangya Hospital of Central South University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study evaluated the efficacy of epalrestat in diabetic peripheral neuropathy and its effects on the central nervous system in diabetic peripheral neuropathy subjects.

Timeline

Start
2022-01
Primary completion
2023-10
Completion
2023-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Epalrestat Small molecule 50 mg Oral
Background methylcobalamin Small molecule 0.5 mg Oral

Indications